Quarterly ResultMay 12, 2026, 07:47 AM
Organigram Q2 Net Loss $0.92M; Revenue Down 9%; Raises FY26 Outlook
AI Summary
Organigram Global reported a net loss of $0.92 million for Q2 Fiscal 2026, a significant decrease from a net income of $42.46 million in Q2 Fiscal 2025, with net revenue declining 9% to $59.79 million. The company recognized a $5.8 million impairment charge due to new US regulatory restrictions affecting hemp-derived products. Subsequent to the quarter, Organigram closed the acquisition of Sanity Group for €107.3 million and updated its Fiscal 2026 guidance, projecting net revenue to exceed $350 million and Adjusted EBITDA to surpass Fiscal 2025 performance.
Key Highlights
- Organigram reported Q2 Fiscal 2026 net revenue of $59.79 million, down 9% from Q2 Fiscal 2025.
- The company posted a Q2 Fiscal 2026 net loss of $0.92 million, compared to a net income of $42.46 million in Q2 Fiscal 2025.
- Adjusted EBITDA for Q2 Fiscal 2026 was $0.87 million, an 82% decrease from $4.91 million in Q2 Fiscal 2025.
- A $5.8 million impairment charge on intangible assets was recognized due to new US regulatory restrictions on hemp-derived products.
- Subsequent to the quarter, Organigram acquired Sanity Group for an upfront price of €107.3 million.
- Fiscal 2026 net revenue guidance was updated to exceed $350 million, up from the previous $300 million.
- Fiscal 2026 Adjusted EBITDA is now projected to exceed Fiscal 2025 performance.
- The company expects to sell or restructure its US hemp-derived THC product activities by November 2026 due to regulatory changes.